The recalls affect three lots of losartan manufactured by Torrent Pharmaceuticals and 40 lots of losartan manufactured by Camber Pharmaceuticals.
In both cases, trace amounts of N-Nitroso N-Methyl 4-aminobutyric acid were detected in the medication. NMBA is a known animal carcinogen, and may cause cancer in humans.
This is the second recall issued due to the presence of NMBA. On March 1, Hetero Labs in India issued a recall of 87 lots of the tablets.
While this is only the second recall linked to the presence of NMBA, there have been two other likely carcinogenic impurities — N-Nitrosodimethylamine and N-Nitrosodiethylamine — detected in generic blood pressure drugs irbesartan and valsartan. As a result, there have been hundreds of recalls of generic blood pressure medications.
Find more about the recall notices here.
More articles on pharmacy:
Harvard gets $100M infusion for drug research from hedge fund
Purdue Pharma CEO: Bankruptcy is ‘an option’ amid lawsuits
Intermountain CEO Dr. Marc Harrison: How Civica Rx will disrupt the drug industry
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
